ipodystrophy in human immunodeficiency virus-infected patients: a randomised, open-label study with rosiglitazone and metformi
Not Applicable
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)Infections and Infestations
- Registration Number
- ISRCTN36766542
- Lead Sponsor
- GlaxoSmithKline (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
HIV-Ribonucleic Acid (RNA) values less than 10,000 copies/ml, the presence of lipodystrophy, and treatment with Highly Active Anti-Retroviral Therapy (HAART) for at least 18 months with no changes in the treatment regimen during six months prior to inclusion.
Exclusion Criteria
1. The presence of opportunistic infectious disease or malignancies, renal-, thyroid- and/or liver disease
2. Body Mass Index (BMI) more than 30 kg/m^2
3. Fasting plasma glucose more than 7 mmol/l
4. Triglycerides more than 10 mmol/l and/or total cholesterol more than 8 mmol/l
5. Alcohol intake more than three units (36 g) per day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method